Do CBD Gummies Show up on Drug Tests?
BD can be an excellent way to enhance wellness, promote well-being, and encourage relaxation. CBD lovers worldwide often enjoy many potential benefits. They may consume various forms of CBD throughout their day. One of the most innovative ways users get their boost of CBD is from gummies. CBD gummies are delectable treats that have a burst of CBD. Many consumers enjoy taking this snack on the go or for sharing with friends.
However, there are still ongoing discussions surrounding CBD’s status, both federally and within states. Due to this issue, it’s understandable that consumers may feel some trepidation. This is especially true when it comes to blood work for employment. Many users may want to know, “Will I have a CBD positive drug test?”
CBD in drug tests may not have a straightforward answer. It may depend on a few factors, including quality. This article will go over these factors and highlight some critical aspects regarding CBD and hemp. We’ll also delve into how high-quality hemp and CBD gummies for sale can make a difference.
What Is CBD?
Before launching into a detailed explanation, the best starting point may include an examination of CBD. CBD or cannabidiol is a substance that growers can harvest from hemp. Unlike marijuana, CBD derived from hemp has minimal THC or tetrahydrocannabinol. Researchers and users alike have cited THC as having intoxicating effects, including intense drowsiness, lethargy, and paranoia.
Studies show that CBD may not induce the physiological reactions often associated with marijuana. In addition to its non-intoxicating nature, CBD may have other potential benefits. Developing bodies of research indicate that CBD may quell symptoms related to anxiety, sleep deprivation, and stress-related syndromes.
Why Worry About Quality?
CBD has become increasingly popular. Consumers can purchase it from a variety of places, including gas stations and other retail outlets. However, the quality of any of these CBD-infused items, including gummies, may be questionable at best. And when it comes to gummies, ensuring that a purchase is premium means buying from a seller that uses industrial hemp. This is especially important for drug tests.
Some may wonder just how industrial hemp relates to drug testing. Well, most drug tests screen for certain drugs and other substances, and this includes THC. Low-quality or subpar hemp may contain a higher level of THC than American industrial hemp. Products derived from industrial hemp, including CBD-infused gummies, typically have minimal amounts of THC.
This translates into a test that won’t indicate THC use. In fact, researchers recently found that a threshold of 15ng/ml of THC is sufficient for a positive urine sample. Most high-grade CBD items from industrial hemp have 0.3% or less THC. And it’s not only where hemp comes from that counts. Extraction methods are essential, as well. When CBD comes from top-notch extraction procedures such as natural CO2, growers can harvest a higher grade of CBD.
Companies that take CBD seriously source their CBD from American farms that adhere to stringent growing practices. They may also ensure the best ways of getting CBD, including CO2 extraction. The result is a low-THC product with little chance of affecting a drug test.
When shopping around, it’s also important to note that reputable companies will often include detailed lab reports. These reports will contain the amount of CBD, THC, and other substances in a given item.
Getting Your Gummies: PureKana Online
Gummies can be an excellent source of CBD. They are transportable, easy to share, and can satisfy a sweet tooth. CBD fans looking for this tasty treat can buy them in a variety of places and cities. Online CBD gummy sellers abound, but not every company is reputable and sources from high-grade hemp.
A company like Purekana offers top of the line gummies with premium ingredients. PureKana’s gummies boast up to 25mg of industrial-hemp derived CBD per serving. Each bottle of their regular or all-vegan gummies features 20 gummies with fruity flavors.
Their gummies also have an added bonus of affordability. They feature price points that won’t bust a budget. And with a responsive customer care team, consumers may find that they have additional security and assistance.
Feb. 21, 2021 12:00 a.m. Marketplace
3 Marijuana Stocks With High Hopes for the Future
Marijuana stocks are enjoying a bit of a renaissance these days. With Joe Biden in the White House and Democrats taking the Senate, bullish investors are hopeful that greener days are ahead. That’s why immediately after Joe Biden’s victory, we saw marijuana stocks gaining a lot of ground.
Nevertheless, some are wondering is whether this is another false dawn. When Canada legalized cannabis on a federal level, many believed it was a watershed moment for the Cannabis industry. Consequently, several investors rushed in, leading to outsized valuations.
After some essential bubble-bursting, companies are now attractively valued. The post-election momentum caused a momentary blip, and more attractive valuations will return soon.
– ADVERTISEMENT –
InvestorPlace – Stock Market News, Stock Advice & Trading Tips
But I digress. Picking quality stocks is never an easy task, especially when you are focusing on a sector that is under the hammer. That’s why you need to separate the wheat from the chaff.
On this list, we include companies that have a strong track record of growth. Stocks will always ebb and flow, depending on the news. However, the companies with excellent performance metrics will continue to do well, regardless of the wider industry’s external circumstances.
So, without further ado, here are three marijuana stocks that will push your returns higher:
Marijuana Stocks To Buy: GW Pharmaceuticals (GWPH)
Source: Shutterstock
GWPH stock soared 46% after Jazz Pharmaceuticals(NASDAQ:JAZZ) agreed to a $7.2 billion acquisition of the CBD biopharma in a cash-and-stock deal expected to close in the second quarter.
GW Pharmaceuticals is a biopharmaceutical company developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, Epidiolex, in a broad range of disease areas.
Epidiolex is a liquid formulation of pure plant-derived cannabidiol used to treat several rare childhood-onset epilepsy disorders. The company also develops and markets Sativex, an oromucosal spray for spasticity treatment due to multiple sclerosis.
GWPH is a very consistent performer, having exceeded analyst expectations in the past six quarters consecutively. It will boost profits of its new parent with double-digit revenue growth of 41% next year.
Valuation is also a plus for this one. Recently, many pure-plays in the cannabis space have skyrocketed on the back of positive news. Valuations are now outsized. However, GWPH stock trades at 13.5 times price-to-sales. Not too bad, considering the recent blockbuster merger.
Aphria (APHA)
Source: Shutterstock
Aphria does not have exposure to the U.S. CBD or THC markets due to federal prohibition constraints. Nonetheless, now that the Democrats are in power, we can see headway on that end.
Aphria operates through retail and wholesale channels in Canada and internationally. It has operations in over 10 countries outside of Canada and is the main distributor of medical cannabis to Germany.
Although not having a U.S. presence is its main Achilles heel, it does have some exposure in the form of SweetWater, a craft brewery. Aphria closed the acquisition last year.
CEO and Chairman Irwin Simon said the purchase would allow the Canadian licensed producer to build brand awareness in the U.S. ahead of federal legalization.
In the past five years, sales have grown 179.6% on average. Looking ahead, it’s expected that the company will increase sales by 31.5% next year. For all this, if you get shares for just 9.8 times P/S, I’d say it’s a steal.
Marijuana Stocks To Buy: OrganiGram Holdings (OGI)
Source: Shutterstock
OrganiGram Holdings focuses on producing indoor-growth cannabis for patients and adult recreational consumers and developing overseas business partnerships.
Its brand portfolio includes Edison Reserve, Edison Cannabis Co, ANKR Organics, and Trailblazer.
OrganiGram has disappointed investors with its sluggish revenue growth and cash burn. But analysts are expecting the next year to bring some relief. Sales and EPS are expected to grow 64.1% and 320.0%, leading to a bullish reading. OGI stock is up 77.4% in the last month. But shares are still trading at 11.2 times price-to-earnings.
OGI has outperformed the S&P 500 by 185.1% and its sector by 198.2% in the past five years. That kind of performance is rare, but investors will ideally want some improvement in fundamentals to accompany this. All the data points to the company turning the corner soon. Until then, the general euphoria regarding the sector will continue to drive shares higher.
On the date of publication, Faizan Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.
Faizan Farooque is a contributing author for InvestorPlace.com and numerous other financial sites. Faizan has several years of experience analyzing the stock market and was a former data journalist at S&P Global Market Intelligence. His passion is to help the average investor make more informed decisions regarding their portfolio.
More From InvestorPlace
- Why Everyone Is Investing in 5G All WRONG
- Top Stock Picker Reveals His Next Potential Winner
- It doesn’t matter if you have $500 in savings or $5 million. Do this now.
- #1 Stock for the Green Energy Boom
The post 3 Marijuana Stocks With High Hopes for the Future appeared first on InvestorPlace.
Tilray CEO says he expects U.S. federal cannabis legalization within two years
Brendan Kennedy, CEO of Canadian cannabis company Tilray, is optimistic that the United States will take steps toward federal legalization of marijuana in the near future, a move that will shake the industry forever.
“I expect that pressure from the North and the South will ultimately lead the U.S. to implement a federal program here at some point in the next 18 to 24 months,” Kennedy said in an interview on CNBC’s “Squawk on the Street” Wednesday.
Earlier this month, Mexico published regulations for medical cannabis use and Kennedy is confident that Mexico and Canada’s positive stance on marijuana will put more pressure on the U.S.
Tilray announced Tuesday that it has been chosen as a supplier of medical cannabis for experimentation in France by the country’s National Agency for the Safety of Medicines and Health Products.
Since 2017, the company has been selling its cannabis products in Germany. With the French program getting underway in the first quarter, Kennedy is optimistic that other European countries will implement medical marijuana programs as well.
“While we are excited for our opportunities in Germany and France, we expect to see additional opportunities for our European businesses in the coming quarters,” Kennedy told CNBC in an interview.
Tilray has cannabis production licenses in Canada and Portugal, where their main cannabis facility is located.
Has San Francisco reached its COVID peak?
While California’s rollout of the COVID-19 vaccine continues to be bumpy amid the deadliest days of the pandemic, the latest numbers on new cases and hospitalizations from the San Francisco Department of Public Health reveal the surge may be easing in the city.
In a Tuesday update, San Francisco Health Director Dr. Grant Colfax said while the number of new daily cases remains higher than before the explosion of cases after Thanksgiving, the most recent data shows promising signs. The case rate is currently 38.3 per 100,000 people, down slightly from the high of 42.5 new cases per 100,000 on Jan. 10.
“This trend is promising, but it’s too early to know for sure so we simply can not let our guard down,” Colfax said. “Our current number per 100,000 is far higher than our summer surge when we peaked at just 15.4, but we are still doing better than California as a whole where the average is 100.9 per 100,000.” (Note: According to the Centers for Disease Control and Prevention, the rate per 100,000 in California was 90.3 as of Jan. 20.)
The post-holiday rise in hospitalizations is beginning to trend down “just barely” with the weekly change in hospitalization rate declining by 1%, Colfax said.
“That rate in change is important because it reflects the demand put on our hospitals for acute care and ICU beds to care for COVID-19 and other patients,” he noted. “Again, this is promising and hopeful news.”
With cases finally starting to decline slightly and the distribution of vaccines slowly increasing, some may be wondering: Did San Francisco hit its peak?
“I think the answer is yes,” said UCSF epidemiologist Dr. George Rutherford. “We’ve seen the positivity rate start to go down. We’ve seen cases start to go down. We’re seeing hospitalizations go down. We’ll start to see ICU admissions go down and then we’ll see deaths go down. So I say yeah, probably. It think we’re on our way down.”
Rutherford said this with caution, noting that numbers can easily increase if people stop wearing masks and social distancing. “You have to be careful,” he warned. “It could bounce right back up.”
Health officials are in a race against time, not only as patients continue to become sick and die but as the virus mutates into forms that can spread much more easily.
An L452R variant has been found in at least a dozen counties and was identified in several large outbreaks in Santa Clara, San Francisco and Monterey counties.
Rutherford believes the new variants are unlikely to cause a major surge in San Francisco if people wear their face coverings, don’t gather and follow public health guidelines.
“What causes outbreaks is people not wearing masks and not socially distancing and getting into crowded situations,” he said. “If it’s one strain or another, they all cause outbreaks. Some may transmit more than others, but at the end of the day it’s all behavioral.”
UCSF infectious disease doctor Dr. Peter Chin-Hong agreed numbers are trending slightly down, but he’s hesitant to say S.F. hit its highest peak; Chin-Hong is worried about the L452R variant, which is increasingly being identified in cases.
“That rate of increase is making me worry it’s going to be the U.K. variant all over again,” Chin-Hong said. “It’s becoming a larger part of the genotype scene. It suggests it’s taking over the COVID.”
He said he also worries people will become less vigilant in following the public health orders. “Just when it’s getting warm and the vaccine hope is there, I’m worried we’ll slack off,” said Chin-Hong, noting that people will still need to wear masks after they’ve been vaccinated. “Until there’s consistency in the numbers, I can’t say for certain we’ve hit the peak.”
Across California, infection indicators are “all showing trends in the right direction,” state Health and Human Services Secretary Dr. Mark Ghaly said. A surge following Christmas and New Year’s had been feared on top of the surge after Halloween and Thanksgiving that drove case levels and hospitalizations to record levels.
Only a couple of weeks ago, it was feared some hospitals in Los Angeles and other hard-hit areas might have to begin rationing care as they ran out of surge capacity as regular beds were filled.
But statewide hospitalizations are down 8.5% over 14 days, with the number of intensive care patients also easing. Hospitals that had been seeing 3,500 new patients each day are now seeing 2,500 to 2,900 daily admissions — still distressingly high, but “quite a significant reduction,” Ghaly said.
When Cannabis Came Out: Remembering Prop 215
Recently, SF Weekly journalist Veronica Irwin went out on a limb and exclaimed, “It’s because of gay activism that Californians have a regulated cannabis market.”
She rattled off a list of famous gays, without genuinely honoring the foot soldiers, not the superstars of the movement. Guys like Michael Koehn, 74, and David Goldman, 69, a gay couple, who met in 1988 and married in 2008. Both have spread the ganja gospel far and wide, and both have benefitted from recreational and medicinal weed. When I visited them in the Castro District, they shared their favorite cannabis products with me—along with their own individual stories that tell much of the bigger picture.
After Michael Koehn graduated from the University of Wisconsin, he worked for the San Francisco Recreation & Parks Department. He tells me he’s never been in the closet as a gay man. “I didn’t think to be secretive, though coming out caused friction with my mom,” he says. “I explained to her, ‘I have to be who I am.’” But while Koehn was out of the gay closet, he was in the cannabis closet. “So was everyone else,” he says. “We smoked on the sly, brands like Acapulco Gold.”
Dave Goldman, an ex-New Yorker and a graduate of the University of Chicago, taught generations of school kids in Marin. “In the 1970s, to be openly gay was fraught with perils,” he tells me. “Jobs were threatened.” Goldman first used cannabis at 18. He hasn’t ever stopped. “It’s been downhill all the way,” he says.
Goldman wisely kept cannabis separate from his day job. “I didn’t socialize with colleagues,” he says. In San Francisco, all through the HIV/AIDS epidemic of the 1980s, Goldman lost friends. So did Koehn, who attributes his survival to a half-dozen factors. “I have good genes, I was in support groups and I had good luck,” he says. “Cannabis gave me an appetite, eased my nausea and provided relief from pain.”
In the wake of the HIV/AIDS epidemic and with savvy lobbying by Dennis Peron and others, plus nifty maneuvering by San Francisco D.A. Terence Hallinan, Californians approved medical marijuana in 1996. After Prop. 215 passed, Koehn and Goldman were out of the cannabis closet for good.
With Covid-19, they practice all the prudent things. “This is our second pandemic,” Koehn says. “Two more than we wanted.” Covid-19 hasn’t deterred them from their cannabis activism, which links them to NORML, Americans for Safe Access (ASA) and the San Francisco dispensary, Green Cross, where they sit on the board of directors. “Cannabis isn’t just about getting high,” Goldman says. “It’s about everyone getting educated about marijuana.” This winter, Goldman and Koehn fly to Florida for much needed R and R. Bon voyage, guys.
Jonah Raskin is the author of “Marijuanaland: Dispatches from an American War.”
2 Top Marijuana Stocks to Buy in January
Marijuana stocks have been on fire lately. Many investors are hoping that a Democratic-controlled senate will steer the U.S. on the path to decriminalization — or even to legalization of the drug at the federal level. If — and it’s a big “if” — legalization did happen, it would create the world’s biggest cannabis industry with over $100 billion in annual sales.
In the past month, the Horizons Medical Marijuana Life Sciences ETF(TSX:HMMJ), a leading indicator of pot stocks, is already up over 12%. That’s just below the S&P 500’s 12.8% return over the same period. Given all the enthusiasm, let’s take a look at two of the best marijuana companies to choose from this January.
1. Aphria
Aphria (NASDAQ:APHA) and medical cannabis company Tilray (NASDAQ:TLRY) will merge this year to form the biggest marijuana grower in the world, with nearly 900 million Canadian dollars in annual revenue. The combined entity is well positioned to expand into the U.S. cannabis market, with its line of beverages and cannabidiol (CBD) products available at tens of thousands of retail locations throughout North America.
During the fiscal second quarter of 2021 (ended Nov. 30, 2020), Aphria increased its sales by 33% year over year to CA$160.5 million. Simultaneously, its cash production cost per gram of cannabis fell 6% quarter over quarter to CA$0.79. After adjusting for changes in its convertibles’ fair value, one-time transaction costs, and share compensation expenses, the company posted a surprise profit of CA$0.01 per share.
It is quite remarkable for a pot grower to become profitable while it is expanding. The company’s free cash flow also improved by as much as CA$70 million over the past quarter.
Right now, Aphria sees significant demand for its Canadian pot business as well. It managed to sell approximately 26,730 kilograms of cannabis in Q2 2021, up from 20,880 kg sold in the previous quarter. Given the potential for its momentum to continue, I highly recommend marijuana investors pick up shares of Aphria, even while it’s trading at about eight times revenue.
2. HEXO
Pot grower HEXO (NYSE:HEXO) sports the largest market share in the Canadian province of Quebec. It, too, is eyeing the multi-billion cannabis opportunity south of the border. Currently, HEXO runs a joint venture with Molson Coors Brewing Company (NYSE:TAP) to develop its line of CBD-infused beverages. The partnership’s CBD sparkling water was just launched in Colorado.
Despite being a relatively new venture, its beverages are already wildly successful. HEXO now holds a 54% market share in Canada’s cannabis drinks industry, a title previously held by Canopy Growth (NASDAQ:CGC).
Back in the first quarter of 2021 (ended Oct. 31), HEXO’s beverage revenue totaled CA$3 million, a sizable increase over the CA$2 million it brought in during the previous quarter. Moreover, the company managed to break even in terms of gross profit, compared to a negative gross margin of 121% in the fourth quarter of 2020.
It also should be noted that HEXO is more than doubling its sales year after year and is very close to breaking even. Furthermore, its CA$150 million in cash more than offsets the company’s CA$59 million in debt and convertibles. Trading at about 9 times revenue, HEXO’s growth premium is well worth it. Investors should expect the company to break past its earnings estimate as it makes the most of its leading role with its pot beverage brands.
Here’s The Marijuana Stock You’ve Been Waiting For
A little-known Canadian company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.
And make no mistake – it is coming.
Cannabis legalization is sweeping over North America – 15 states plus Washington, D.C., have all legalized recreational marijuana over the last few years, and full legalization came to Canada in October 2018.
And one under-the-radar Canadian company is poised to explode from this coming marijuana revolution.
Because a game-changing deal just went down between the Ontario government and this powerhouse company…and you need to hear this story today if you have even considered investing in pot stocks.
The Different Types of Medical Marijuana and Their Effects
If you’re new to medical marijuana, it helps to know that there are two strains of marijuana: Cannabis Indica and Cannabis Sativa. Established in the 18th century, these two classifications were made by scientists who noted definite differences in the two strains’ makeup and resin production, appearance, flowering time, flavor, and yields.
The Two Strains Explained
Cannabis professionals and many medical marijuana users claim that the two strains vary greatly in the effects they deliver and the symptom relief they provide. In the medical marijuana community, the Indica strain is known to provide a sedative effect, providing a full-body relaxation and calm. The Sativa strain, on the other hand, has an uplifting, energizing effect. For people suffering from chronic pain, multiple sclerosis, muscle spasms, fibromyalgia, or nausea, the Indica strain tends to provide the most symptom relief. For people with depression, ADHD, fatigue, or other mood disorders, the Sativa strain is the best option.
Is There Really a Difference?
Some scientists believe that there is no real difference in the effects provided by the two strains. They claim that the differing effects aren’t really rooted in reality, but in what the user expects the effects to be. Whether this claim is true or not is still up for debate, but what is known is that cannabis affects each person differently – regardless of the strain.
If you’re in San Bruno or elsewhere in San Mateo County and have a valid medical marijuana card, be sure to visit Elevated of San Francisco to learn more about how our cannabis products can help you find relief from your symptoms. Elevated serves patients by providing quality marijuana products and a personalized in-store experience.
A Short History on Medical Marijuana
Medical marijuana has been around since ancient times. The ancient Chinese talk about cannabis and its therapeutic properties for gout, constipation, rheumatism, and senility in old writings. In fact, Chinese Emperor and pharmacologist, Shennong, described using cannabis for medical reasons in a book published in 2737 BC.
Medical Marijuana in the United States
Medical marijuana has always been considered a viable treatment option in the United States. Unfortunately, in 1937, the federal government outlawed its use in defiance of the American Medical Association. From that point, medical cannabis was only available to a select few through the Investigational New Drug (IND) program. Once part of the program, patients could receive up to nine pounds of marijuana a year.
For years, the American public was largely blocked from obtaining marijuana for medical use. It wasn’t until the 1990s that voters began demanding that the weed be legalized for medical purposes. California, through Proposition 215, became the first state to legalize medical marijuana in 1996. Since California’s bold move in the late ’90s, dozens of other states have followed suit and made medical marijuana legal.
Today, more than half of the US population has access to cannabis as a medical treatment. The sad news is that at a federal level, marijuana of any kind is still illegal. In October 2009, however, the federal government stated it would not penalize citizens who hold valid medical marijuana cards or the distributors who follow state laws.
If you live in San Francisco or Daly City and you hold a medical marijuana card, Elevated of San Francisco is the best marijuana dispensary in the area. Offering a wide array of cannabis products for both medical treatment and recreational use, every visitor is sure to find exactly what they’re looking for.
COMMENTS 5 Popular Uses for Medical Marijuana
As more and more states legalize marijuana, it appears that the popularity of alternative medicine is on the rise. In San Francisco alone, people turn to not only medicinal marijuana but also aromatherapy, crystal therapy, acupuncture and more to reduce pain, eliminate anxiety and fight the effects of aging. Medical marijuana is used in a host of situations, with the following five uses being among the most popular.
1. Reduce Nausea and Vomiting
Cannabis works in the body to dull the senses. When taken orally in pill form, it can reduce or eliminate nausea and/or vomiting associated with chemotherapy in cancer patients. In fact, studies show that medical marijuana actually works better than most FDA-approved medications given for this purpose.
2. Stimulate Appetite
For cancer and HIV-infected individuals, taking medical marijuana helps to increase appetite, which in turn stops weight loss.
3. Reduce Muscle Tension and Spasm
When medical marijuana with high THC levels is given to MS patients, it helps relax muscles and reduce spasms and tremors significantly. A liquid form of the drug containing THC and cannabidiol seems to be the most effective for this purpose.
4. Pain Reduction
People suffering from chronic pain associated with such ailments as MS, HIV, alcoholism, spinal injury, amputation, etc. find significant relief of their pain after using medical marijuana.
5. Trouble Sleeping
In addition to providing pain relief, people who smoke marijuana tend to have less anxiety and fewer instances of sleep problems such as insomnia. Furthermore, people who use marijuana report improved mood and overall well-being in general. If you are in the San Francisco Bay area and would like to know more about medical marijuana and how to get it, contact Elevated of San Francisco. The knowledgeable staff can help you manage your symptoms and find relief fast.